Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh?
Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis o...
Gespeichert in:
| Veröffentlicht in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2016-02, Vol.16 (2), p.111-115 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 115 |
|---|---|
| container_issue | 2 |
| container_start_page | 111 |
| container_title | Clinical lymphoma, myeloma and leukemia |
| container_volume | 16 |
| creator | Hossain, Nasheed Mohammad Klumpp, Thomas Ulicny, John Garner, Michael Kropf, Patricia Lamont Mangan, Kenneth F Barta, Stefan Klaus Fung, Henry C Martin, Mary Ellen |
| description | Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis of 63 patients, we found that there was no difference in outcomes based on the type of cells used for DLI. However, in a subset of 32 patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), the use of cryopreserved cells appears to have resulted in improved event-free survival (EFS) in patients who underwent myeloablative transplantation. |
| doi_str_mv | 10.1016/j.clml.2015.10.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1761081734</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S2152265015013361</els_id><sourcerecordid>1761081734</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-80b1fd90955a888e631c7f6a5dcd2e3578116a421665ffa9cfac1340e9d1ca7a3</originalsourceid><addsrcrecordid>eNp9kc-KFDEQxoMo7h99AQ_SRy8zViXd6W4QRfbvwCwe1HPIpKt3M6aTMekW5uZD7BPuk5hm1j14EAIVqr7vg_oVY28Qlggo32-Xxg1uyQGr3FgClM_YMceKL7iU7fOnfwVH7CSlLUANgO1LdpTngkMtj9nqPPgQi_V-2N0Fsx-pWPl-Sjb4wvrimgY9BhdurSlutLO3XntjKT38vr8KoSvGUGyouIyU7j69Yi967RK9fqyn7Pvlxbez68X6y9Xq7PN6YcoGx0UDG-y7Ftqq0k3TkBRo6l7qqjMdJ1HVDaLUJUcpq77Xrem1QVECtR0aXWtxyt4dcncx_JwojWqwyZBz2lOYksJaIjRYizJL-UFqYkgpUq920Q467hWCmhGqrZoRqhnh3MsIs-ntY_60Gah7svxllgUfDgLKW_6yFFXKTLyhzkYyo-qC_X_-x3_sxllvjXY_aE9pG6boMz-FKnEF6ut8xPmGmJ8QEsUf-vSXPw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1761081734</pqid></control><display><type>article</type><title>Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hossain, Nasheed Mohammad ; Klumpp, Thomas ; Ulicny, John ; Garner, Michael ; Kropf, Patricia Lamont ; Mangan, Kenneth F ; Barta, Stefan Klaus ; Fung, Henry C ; Martin, Mary Ellen</creator><creatorcontrib>Hossain, Nasheed Mohammad ; Klumpp, Thomas ; Ulicny, John ; Garner, Michael ; Kropf, Patricia Lamont ; Mangan, Kenneth F ; Barta, Stefan Klaus ; Fung, Henry C ; Martin, Mary Ellen</creatorcontrib><description>Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis of 63 patients, we found that there was no difference in outcomes based on the type of cells used for DLI. However, in a subset of 32 patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), the use of cryopreserved cells appears to have resulted in improved event-free survival (EFS) in patients who underwent myeloablative transplantation.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2015.10.004</identifier><identifier>PMID: 26632076</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Disease-Free Survival ; Donor lymphocyte infusion (DLI) ; Event-free survival ; Follow-Up Studies ; Hematologic Neoplasms - therapy ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Transplantation - methods ; Humans ; Lymphocyte Transfusion - methods ; Neoplasm Recurrence, Local - therapy ; Overall survival ; Persistent or relapsed disease ; Retrospective Studies ; Tissue Donors</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2016-02, Vol.16 (2), p.111-115</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-80b1fd90955a888e631c7f6a5dcd2e3578116a421665ffa9cfac1340e9d1ca7a3</citedby><cites>FETCH-LOGICAL-c481t-80b1fd90955a888e631c7f6a5dcd2e3578116a421665ffa9cfac1340e9d1ca7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2152265015013361$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26632076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hossain, Nasheed Mohammad</creatorcontrib><creatorcontrib>Klumpp, Thomas</creatorcontrib><creatorcontrib>Ulicny, John</creatorcontrib><creatorcontrib>Garner, Michael</creatorcontrib><creatorcontrib>Kropf, Patricia Lamont</creatorcontrib><creatorcontrib>Mangan, Kenneth F</creatorcontrib><creatorcontrib>Barta, Stefan Klaus</creatorcontrib><creatorcontrib>Fung, Henry C</creatorcontrib><creatorcontrib>Martin, Mary Ellen</creatorcontrib><title>Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh?</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><description>Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis of 63 patients, we found that there was no difference in outcomes based on the type of cells used for DLI. However, in a subset of 32 patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), the use of cryopreserved cells appears to have resulted in improved event-free survival (EFS) in patients who underwent myeloablative transplantation.</description><subject>Disease-Free Survival</subject><subject>Donor lymphocyte infusion (DLI)</subject><subject>Event-free survival</subject><subject>Follow-Up Studies</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Humans</subject><subject>Lymphocyte Transfusion - methods</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Overall survival</subject><subject>Persistent or relapsed disease</subject><subject>Retrospective Studies</subject><subject>Tissue Donors</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc-KFDEQxoMo7h99AQ_SRy8zViXd6W4QRfbvwCwe1HPIpKt3M6aTMekW5uZD7BPuk5hm1j14EAIVqr7vg_oVY28Qlggo32-Xxg1uyQGr3FgClM_YMceKL7iU7fOnfwVH7CSlLUANgO1LdpTngkMtj9nqPPgQi_V-2N0Fsx-pWPl-Sjb4wvrimgY9BhdurSlutLO3XntjKT38vr8KoSvGUGyouIyU7j69Yi967RK9fqyn7Pvlxbez68X6y9Xq7PN6YcoGx0UDG-y7Ftqq0k3TkBRo6l7qqjMdJ1HVDaLUJUcpq77Xrem1QVECtR0aXWtxyt4dcncx_JwojWqwyZBz2lOYksJaIjRYizJL-UFqYkgpUq920Q467hWCmhGqrZoRqhnh3MsIs-ntY_60Gah7svxllgUfDgLKW_6yFFXKTLyhzkYyo-qC_X_-x3_sxllvjXY_aE9pG6boMz-FKnEF6ut8xPmGmJ8QEsUf-vSXPw</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Hossain, Nasheed Mohammad</creator><creator>Klumpp, Thomas</creator><creator>Ulicny, John</creator><creator>Garner, Michael</creator><creator>Kropf, Patricia Lamont</creator><creator>Mangan, Kenneth F</creator><creator>Barta, Stefan Klaus</creator><creator>Fung, Henry C</creator><creator>Martin, Mary Ellen</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160201</creationdate><title>Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh?</title><author>Hossain, Nasheed Mohammad ; Klumpp, Thomas ; Ulicny, John ; Garner, Michael ; Kropf, Patricia Lamont ; Mangan, Kenneth F ; Barta, Stefan Klaus ; Fung, Henry C ; Martin, Mary Ellen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-80b1fd90955a888e631c7f6a5dcd2e3578116a421665ffa9cfac1340e9d1ca7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Disease-Free Survival</topic><topic>Donor lymphocyte infusion (DLI)</topic><topic>Event-free survival</topic><topic>Follow-Up Studies</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Humans</topic><topic>Lymphocyte Transfusion - methods</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Overall survival</topic><topic>Persistent or relapsed disease</topic><topic>Retrospective Studies</topic><topic>Tissue Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hossain, Nasheed Mohammad</creatorcontrib><creatorcontrib>Klumpp, Thomas</creatorcontrib><creatorcontrib>Ulicny, John</creatorcontrib><creatorcontrib>Garner, Michael</creatorcontrib><creatorcontrib>Kropf, Patricia Lamont</creatorcontrib><creatorcontrib>Mangan, Kenneth F</creatorcontrib><creatorcontrib>Barta, Stefan Klaus</creatorcontrib><creatorcontrib>Fung, Henry C</creatorcontrib><creatorcontrib>Martin, Mary Ellen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hossain, Nasheed Mohammad</au><au>Klumpp, Thomas</au><au>Ulicny, John</au><au>Garner, Michael</au><au>Kropf, Patricia Lamont</au><au>Mangan, Kenneth F</au><au>Barta, Stefan Klaus</au><au>Fung, Henry C</au><au>Martin, Mary Ellen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh?</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>16</volume><issue>2</issue><spage>111</spage><epage>115</epage><pages>111-115</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis of 63 patients, we found that there was no difference in outcomes based on the type of cells used for DLI. However, in a subset of 32 patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), the use of cryopreserved cells appears to have resulted in improved event-free survival (EFS) in patients who underwent myeloablative transplantation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26632076</pmid><doi>10.1016/j.clml.2015.10.004</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2152-2650 |
| ispartof | Clinical lymphoma, myeloma and leukemia, 2016-02, Vol.16 (2), p.111-115 |
| issn | 2152-2650 2152-2669 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1761081734 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Disease-Free Survival Donor lymphocyte infusion (DLI) Event-free survival Follow-Up Studies Hematologic Neoplasms - therapy Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation - methods Humans Lymphocyte Transfusion - methods Neoplasm Recurrence, Local - therapy Overall survival Persistent or relapsed disease Retrospective Studies Tissue Donors |
| title | Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A55%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Donor%20Lymphocyte%20Infusion%20in%20Hematologic%20Malignancies%E2%80%94Good%20to%20be%20Fresh?&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Hossain,%20Nasheed%20Mohammad&rft.date=2016-02-01&rft.volume=16&rft.issue=2&rft.spage=111&rft.epage=115&rft.pages=111-115&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2015.10.004&rft_dat=%3Cproquest_cross%3E1761081734%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1761081734&rft_id=info:pmid/26632076&rft_els_id=1_s2_0_S2152265015013361&rfr_iscdi=true |